Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haruda, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haruda, F.
NEUROLOGY 1979;29:1480
© 1979 American Academy of Neurology

Phenytoin hypersensitivity

38 cases

Fred Haruda, M.D.

Harriet Lane Service of the Department of Pediatrics, The Johns Hopkins Hospital, Baltimore, MD.

To determine the frequency and severity of hypersensitivity reactions to phenytoin, we reviewed 38 cases of proven reactions. Patients were included only if no other drugs, including other anticonvulsants, were in use at the time of the reaction. Rashes were most frequent, followed by fever, lymphadenopathy, eosinophilia, abnormal liver function tests, blood dyscrasias, serum sickness, renal failure, and polymyositis. The pseudolymphoma syndrome (fever, rash, and lymphadenopathy) occurred in nine patients. Thirty-five of the 38 reactions occurred within 2 months of the start of therapy. Phenytoin sensitivity accounted for 467 inpatient days during the 14 years of study. Early recognition of phenytoin reactions, prompt drug withdrawal, and appropriate therapeutic measures are necessary to prevent serious morbidity from phenvtoin hypersensitivity.


Address reprint requeststo Dr. Haruda, Box 133, Neurological Institute, Columbia Presbyterian Medical Center, 710 West 168 Street, New York, NY 10032.

Accepted for publication April 16, 1979.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
W. Lu and J. P. Uetrecht
Peroxidase-Mediated Bioactivation of Hydroxylated Metabolites of Carbamazepine and Phenytoin
Drug Metab. Dispos., August 1, 2008; 36(8): 1624 - 1636.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. Nakajima, N. Sakata, N. Ohashi, T. Kume, and T. Yokoi
Involvement of Multiple UDP-glucuronosyltransferase 1A Isoforms in Glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in Human Liver Microsomes
Drug Metab. Dispos., November 1, 2002; 30(11): 1250 - 1256.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
M. C. Carroll, K. A. Yueng-Yue, N. B. Esterly, and B. A. Drolet
Drug-Induced Hypersensitivity Syndrome in Pediatric Patients
Pediatrics, August 1, 2001; 108(2): 485 - 492.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
H. Yamazaki, T. Komatsu, K. Takemoto, M. Saeki, Y. Minami, Y. Kawaguchi, N. Shimada, M. Nakajima, and T. Yokoi
Decreases in Phenytoin Hydroxylation Activities Catalyzed by Liver Microsomal Cytochrome P450 Enzymes in Phenytoin-Treated Rats
Drug Metab. Dispos., April 1, 2001; 29(4): 427 - 434.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
T. Komatsu, H. Yamazaki, S. Asahi, E. M. J. Gillam, F. P. Guengerich, M. Nakajima, and T. Yokoi
Formation of A Dihydroxy Metabolite of Phenytoin in Human Liver Microsomes/cytosol: Roles of Cytochromes P450 2c9, 2c19, and 3a4
Drug Metab. Dispos., November 1, 2000; 28(11): 1361 - 1368.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
L. Cuttle, A. J. Munns, N. A. Hogg, J. R. Scott, W. D. Hooper, R. G. Dickinson, and E. M. J. Gillam
Phenytoin Metabolism by Human Cytochrome P450: Involvement of P450 3A and 2C Forms in Secondary Metabolism and Drug-Protein Adduct Formation
Drug Metab. Dispos., August 1, 2000; 28(8): 945 - 950.
[Abstract] [Full Text]


Home page
Postgrad. Med. J.Home page
H. J Milionis, A. Skopelitou, and M. S Elisaf
Hypersensitivity syndrome caused by amitriptyline administration
Postgrad. Med. J., June 1, 2000; 76(896): 361 - 363.
[Abstract] [Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
L F M Beenen, J Lindeboom, D G A K.-N. Trenite, J J Heimans, F J Snoek, D J Touw, H J Ader, and H A M van Alphen
Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects
J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 474 - 480.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
D. Smith, B.A. Defalla, and D.W. Chadwick
The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic
QJM, January 1, 1999; 92(1): 15 - 23.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. C. Roujeau and R. S. Stern
Severe Adverse Cutaneous Reactions to Drugs
N. Engl. J. Med., November 10, 1994; 331(19): 1272 - 1285.
[Full Text]


Home page
CLIN PEDIATRHome page
N. G. Powers and S. H. Carson
Idiosyncratic Reactions to Phenytoin
Clinical Pediatrics, March 1, 1987; 26(3): 120 - 124.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1979 by AAN Enterprises, Inc.